[ad_1]
De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature 539, 443–447 (2016).
Kaneda, M. M. et al. Macrophage PI3Kγ drives pancreatic ductal adenocarcinoma progression. Cancer Discov. 6, 870–885 (2016).
Okkenhaug, K., Graupera, M. & Vanhaesebroeck, B. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discov. 6, 1090–1105 (2016).
Kaneda, M. M. et al. PI3Kγ is a molecular switch that controls immune suppression. Nature 539, 437–442 (2016).
Bilanges, B., Posor, Y. & Vanhaesebroeck, B. PI3K isoforms in cell signalling and vesicle trafficking. Nat. Rev. Mol. Cell Biol. 20, 515–534 (2019).
Chi, S. G. & Minami, Y. Emerging targeted therapy for specific genomic abnormalities in acute myeloid leukemia. Int. J. Mol. Sci. https://doi.org/10.3390/ijms23042362 (2022).
Kayser, S. & Levis, M. J. Updates on targeted therapies for acute myeloid leukaemia. Br. J. Haematol. 196, 316–328 (2022).
Chaperot, L. et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 97, 3210–3217 (2001).
Pagano, L., Valentini, C. G., Grammatico, S. & Pulsoni, A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br. J. Haematol. 174, 188–202 (2016).
Lane, A. A. Targeting CD123 in AML. Clin. Lymphoma Myeloma Leuk. 20, S67–S68 (2020).
Luskin, M. R. & Lane, A. A. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. Haematologica https://doi.org/10.3324/haematol.2022.282171 (2023).
Andrews, S., Stephens, L. R. & Hawkins, P. T. PI3K class IB pathway. Sci. STKE 2007, cm2 (2007).
Yuan, T. L. & Cantley, L. C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497–5510 (2008).
Courtney, K. D., Corcoran, R. B. & Engelman, J. A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28, 1075–1083 (2010).
Togami, K. et al. Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. Cancer Discov. 12, 522–541 (2022).
Townsend, E. C. et al. The public repository of xenografts enables discovery and randomized phase II-like trials in mice. Cancer Cell 29, 574–586 (2016).
Driehuis, E., Kretzschmar, K. & Clevers, H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat. Protoc. 15, 3380–3409 (2020).
Cancer Genome Atlas Research Networket al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013).
Dohner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345–1377 (2022).
Cignetti, A. et al. The characterization of chemokine production and chemokine receptor expression reveals possible functional cross-talks in AML blasts with monocytic differentiation. Exp. Hematol. 31, 495–503 (2003).
van der Schoot, C. E. et al. Interleukin-6 and interleukin-1 production in acute leukemia with monocytoid differentiation. Blood 74, 2081–2087 (1989).
Du, Y. et al. Toll-like receptor-mediated innate immunity orchestrates adaptive immune responses in HBV infection. Front. Immunol. 13, 965018 (2022).
Duan, T., Du, Y., Xing, C., Wang, H. Y. & Wang, R. F. Toll-like receptor signaling and its role in cell-mediated immunity. Front. Immunol. 13, 812774 (2022).
Arvaniti, E. et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica 96, 1644–1652 (2011).
Cannova, J., Breslin, S. J. P. & Zhang, J. Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases. Front. Med. 9, 288–303 (2015).
Rosenbloom, K. R. et al. ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res. 41, D56–D63 (2013).
Vadas, O. et al. Molecular determinants of PI3Kγ-mediated activation downstream of G-protein-coupled receptors (GPCRs). Proc. Natl Acad. Sci. USA 110, 18862–18867 (2013).
Molina, J. R. et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat. Med. 24, 1036–1046 (2018).
Zaoui, K. & Duhamel, S. RhoB as a tumor suppressor: it’s all about localization. Eur. J. Cell Biol. 102, 151313 (2023).
Guan, X. et al. EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis. Oncogene 39, 7127–7141 (2020).
Shin, S. H., Kim, I., Lee, J. E., Lee, M. & Park, J. W. Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer. Oncogene 39, 5839–5854 (2020).
Lin, K. H. et al. P2RY2–AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. Nat. Cancer 3, 837–851 (2022).
Rane, C. K. & Minden, A. p21 Activated kinase signaling in cancer. Semin. Cancer Biol. 54, 40–49 (2019).
Pandolfi, A. et al. PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood 126, 1118–1127 (2015).
Short, N. J., Rytting, M. E. & Cortes, J. E. Acute myeloid leukaemia. Lancet 392, 593–606 (2018).
Boyd, A. L. et al. Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of human AML recurrence. Cancer Cell 34, 483–498.e5 (2018).
Rathinaswamy, M. K. et al. Structure of the phosphoinositide 3-kinase (PI3K) p110γ–p101 complex reveals molecular mechanism of GPCR activation. Sci. Adv. https://doi.org/10.1126/sciadv.abj4282 (2021).
Stoyanov, B. et al. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 269, 690–693 (1995).
Farge, T. et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 7, 716–735 (2017).
Pei, S. et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-22-1297 (2023).
Pei, S. et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 10, 536–551 (2020).
Kuusanmaki, H. et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica 105, 708–720 (2020).
Zhang, H. et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat. Cancer 1, 826–839 (2020).
Sanson, K. R. et al. Optimized libraries for CRISPR–Cas9 genetic screens with multiple modalities. Nat. Commun. 9, 5416 (2018).
Garcia, E. P. et al. Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer. Arch. Pathol. Lab. Med. 141, 751–758 (2017).
Kluk, M. J. et al. Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies. J. Mol. Diagn. 18, 507–515 (2016).
Cabal-Hierro, L. et al. Chromatin accessibility promotes hematopoietic and leukemia stem cell activity. Nat. Commun. 11, 1406 (2020).
Robinson, J. T. et al. Integrative Genomics Viewer. Nat. Biotechnol. 29, 24–26 (2011).
Mootha, V. K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Navarrete-Perea, J., Yu, Q., Gygi, S. P. & Paulo, J. A. Streamlined tandem mass tag (SL-TMT) protocol: an efficient strategy for quantitative (phospho)proteome profiling using tandem mass tag-synchronous precursor selection-MS3. J. Proteome Res. 17, 2226–2236 (2018).
Rappsilber, J., Ishihama, Y. & Mann, M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal. Chem. 75, 663–670 (2003).
Schweppe, D. K. et al. Characterization and optimization of multiplexed quantitative analyses using high-field asymmetric-waveform ion mobility mass spectrometry. Anal. Chem. 91, 4010–4016 (2019).
Schweppe, D. K., Rusin, S. F., Gygi, S. P. & Paulo, J. A. Optimized workflow for multiplexed phosphorylation analysis of TMT-labeled peptides using high-field asymmetric waveform ion mobility spectrometry. J. Proteome Res. 19, 554–560 (2020).
Eng, J. K., Jahan, T. A. & Hoopmann, M. R. Comet: an open-source MS/MS sequence database search tool. Proteomics 13, 22–24 (2013).
Elias, J. E. & Gygi, S. P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods 4, 207–214 (2007).
Elias, J. E. & Gygi, S. P. Target-decoy search strategy for mass spectrometry-based proteomics. Methods Mol. Biol. 604, 55–71 (2010).
Huttlin, E. L. et al. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174–1189 (2010).
Beausoleil, S. A., Villen, J., Gerber, S. A., Rush, J. & Gygi, S. P. A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat. Biotechnol. 24, 1285–1292 (2006).
Vizcaino, J. A. et al. 2016 Update of the PRIDE database and its related tools. Nucleic Acids Res. 44, D447–D456 (2016).
[ad_2]
Source link
Leave a Reply